anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: High body mass index (BMI) is a risk-factor for stress urinary incontinence (SUI). Mid-urethral sling (MUS) surgery is an effective treatment of SUI. The aim of this study was to investigate if there is an association between BMI at time of MUS-surgery and the long-term outcome at 10 years.
MATERIAL AND METHODS: Women who went through MUS surgery in Sweden between 2006 and 2010 and had been registered in the Swedish National Quality Register of Gynecological Surgery were invited to participate in the 10-year follow-up. A questionnaire was sent out asking if they were currently suffering from SUI or not and their rated satisfaction, as well as current BMI. SUI at 10 years was correlated to BMI at the time of surgery. SUI at 1 year was assessed by the postoperative questionnaire sent out by the registry. The primary aim of the study was to investigate if there is an association between BMI at surgery and the long-term outcome, subjective SUI at 10 years after MUS surgery. Our secondary aims were to assess whether BMI at surgery is associated with subjective SUI at 1-year follow-up and satisfaction at 10-year follow-up.
RESULTS: The subjective cure rate after 10 years was reported by 2108 out of 2157 women. Higher BMI at the time of surgery turned out to be a risk factor for SUI at long-term follow-up. Women with BMI <25 reported subjective SUI in 30%, those with BMI 25-<30 in 40%, those with BMI 30-<35 in 47% and those with BMI ≥35 in 59% (p < 0.001). Furthermore, subjective SUI at 1 year was reported higher by women with BMI ≥30, than among women with BMI <30 (33% vs. 20%, p < 0.001). Satisfaction at 10-year follow-up was 82% among women with BMI <30 vs 63% if BMI ≥30 (p < 0.001).
CONCLUSIONS: We found that higher BMI at the time of MUS surgery is a risk factor for short- and long-term failure compared to normal BMI.
Provided is a contrast agent, whereby it becomes possible to reduce the incidence of contrast-induced nephropathy appropriately. The contrast agent is used in such a manner that the contrast agent is administered to a human body while administering oxygen to the human body at least during the administration of the contrast agent. The administration of oxygen is initiated 15 to 20 minutes before the administration of the contrast agent. The administration of oxygen is carried out through the nose or using a mask at a rate of 1.5 to 4.0 L/min. The contrast agent is, for example, a nonionic iodine contrast agent or an ionic iodine contrast agent. At least during the administration of the contrast agent, 0.9 wt% physiological saline is also administered.
Voriconazole for injection unreconstituted vials should be stored at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Voriconazole for injection is a single dose unpreserved sterile lyophile. From a microbiological point of view, following reconstitution of the lyophile with water for injection, the reconstituted solution should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not be longer than 24 hours at 2° to 8°C (36° to 46°F). Chemical and physical in-use stability has been demonstrated for 24 hours at 2° to 8°C (36° to 46°F). This medicinal product is for single use only and any unused solution should be discarded. Only clear solutions without particles should be used [see Dosage and Administration (2.1)].
Increase in serum bile acids (BAs) in patients with primary biliary cholangitis (PBC) may play a causal role in cholestatic pruritus (itch). Linerixibat is a selective small molecule inhibitor of the ileal bile acid transporter, which blocks re-absorption of BAs in the gastrointestinal tract thereby lowering BAs in the systemic circulation and reducing itch. One consequence is excess BAs in the colon, leading to diarrhea and abdominal pain. GLIMMER (NCT02966834) was a placebo-controlled phase IIb dose-ranging trial of linerixibat once (q.d.) or twice daily (b.i.d.) in adults with moderate to severe pruritus and PBC. To determine the optimal dose for maximum itch reduction while minimizing diarrhea, a kinetic-pharmacodynamic (k-PD) model was developed using data from GLIMMER. The PD end point modeled was worst daily itch, derived from itch score reported by patients b.i.d. A proportional odds model was developed post hoc to indicate the probability of diarrhea occurrence, a patient-reported outcome (GI-5) recorded weekly. The final k-PD model successfully described the effects of linerixibat and placebo on itch. Model simulations were consistent with the observed dose-dependent increase in the average number of itch responders (patients with a ≥ 2-point improvement in itch). This was paralleled by a dose-dependent increase in the probability of higher diarrhea frequency scores. The b.i.d. dosing regimens led to a modest increase in the number of itch responders as compared with q.d. dosing. This quantitative framework highlights the trade-off between benefit and tolerability and supported the selection of 40 mg b.i.d. in the phase III GLISTEN trial (NCT04950127).
PURPOSE: Kidney transplantation has a survival benefit for people with human immunodeficiency virus (HIV) and end-stage kidney disease, however increased rates of rejection remain an issue. Questions remain regarding the impact of induction immunosuppression therapy and antiretroviral (ARV) choice on long-term outcomes.
METHODS: We performed a multicenter retrospective analysis of outcomes in recipients with HIV who received kidneys from donors without HIV transplanted between 2004 and 2019. The association between induction and ARV regimens and long-term outcomes including rejection, graft, and recipient survival over 5 years was investigated using Cox regression modeling.
RESULTS: Seventy-eight kidney transplants (KT) performed in 77 recipients at five US transplant centers were included, with median follow up of 7.1 (4.3-10.7) years. Overall recipient and graft survival were 83% and 67%, respectively. Rejection occurred in 37% (29/78). Recipients with rejection were more likely to be younger, recipients of deceased donor organs, and Black. Receipt of rabbit anti-thymocyte globulin (rATG) induction without protease-inhibitor (PI)-based ARVs was associated with 83% lower risk of rejection (adjusted hazard ratio (aHR) 0.17 (95% CI 0.05-0.63), p =.007) and a non-statistically significantly lower risk of graft failure (aHR 0.18 (0.03-1.16), p =.07) when compared to those who received other induction and ARV combinations.
CONCLUSIONS: In this multicenter retrospective study, we found a trend toward lower rejection and improved graft survival among those who received both rATG for induction and PI-sparing ARVs.
Patients undergo low dose TSEBT for 2 weeks. After 30 days of observation, patients receive mechlorethamine hydrochloride gel topically daily at week 7 and then once weekly up to week 54.
Despite frozen donkey semen demonstrating high quality after thawing and achieving suitable pregnancy rates in mares, it yields unsatisfactory results in jennies, likely due to a stronger uterine inflammatory response. This study assessed the effects of platelet-rich plasma (PRP) on uterine inflammation and pregnancy rates in jennies inseminated with frozen donkey semen. Estrous cycles from 11 jennies were assigned to three groups: Control (CTR, n = 22) with no treatment; Single PRP infusion (S-PRP, n = 22) administered 30 h after ovulation induction, prior to artificial insemination (AI); and Double PRP infusion (D-PRP, n = 21) with the first infusion at 30 h after ovulation induction and the second 4 h after AI. Insemination was performed with frozen donkey semen (1 billion sperm) deposited deeply in the uterine horn immediately after ovulation. Endometrial edema, intrauterine fluid (IUF), uterine vascularization, and endometrial cytology were evaluated pre-AI (TCt) and post-AI (6, 24, and 48 h). Uterine biopsies were taken at T48 for histopathological and collagen evaluation. Peripheral blood samples were collected on D5 for serum progesterone measurement, and pregnancy was evaluated via ultrasonography on D14. Data were analyzed using GLMMs, ANOVA, Friedman, and Kruskal-Wallis tests in SAS and GraphPad Prism, with significance set at p < 0.05. The S-PRP group showed less IUF accumulation than the CTR group at T6. Other parameters showed no significant differences among the groups. Cytology revealed a high percentage of inflammatory cells at T6 in all groups, which decreased in subsequent evaluations. In the CTR group, neutrophil percentages were similar to TCt at T24, while treated groups reached this similarity only by T48. Eosinophil percentages increased over time only in the treated groups. Pregnancy rates showed no differences among the groups (CTR: 0 %, S-PRP: 0 %, D-PRP: 10 %). Results indicate that PRP treatments were ineffective in modulating uterine inflammation and did not enhance pregnancy rates in jennies inseminated with frozen donkey semen.
The present invention relates to a novel compound represented as by formula (I). The present invention also provides a novel strain named as  Alternaria alternata  var.  monosporus , which can produce the compound of formula (I). The inventive strain is cultured in the medium to produce and mass the inventive compound of formula (I) in the strain and the medium. The inventive compound of formula (I) is obtained by recovering and purifying from the mycelia and medium. The compound has strong bioactivity of against cancer, fungi and viruses.
New polynucleotide sequences are claimed which (a) are derived from regions coding for the RESA antigen of Plasmodium falciparum, (b) hybridise with the sequence (a), (c) are related to sequences (a) or (b) or (d) on expression codes for a polypeptide derived from the RESA antigen of P. falciparum or which displays similar biological or immunological activity to the polypeptide. Also claimed are recombinant DNA molecules contg. the polynucleotide sequences and hosts transformed with the recombinant DNA. - Various fragments of RESA DNA are prepd. by restriction with enzymes, shearing by sonication or by digestion with enzymes DNase I of Bal31. The isolated fragments of RESA DNA are then enzymatically linked 'head to tail' to form inframe multimers of these fragments. Recombinant DNA molecules have an expression control sequence operatively linked to the DNA.
Phosphorus has a number of important functions in the biochemistry of the body. The bulk of the body's phosphorus is located in the bones, where it plays a key role in osteoblastic and osteoclastic activities. Enzymatically catalyzed phosphate-transfer reactions are numerous and vital in the metabolism of carbohydrate, lipid and protein, and a proper concentration of the anion is of primary importance in assuring an orderly biochemical sequence. ln addition, phosphorus plays an important role in modifying steady-state tissue concentrations of calcium. Phosphate ions are important buffers of the intracellular fluid, and also play a primary role in the renal excretion of the hydrogen ion.

Oral administration of inorganic phosphates increases serum phosphate levels. Phosphates lower urinary calcium levels in idiopathic hypercalciuria.

In general, in adults, about two thirds of the ingested phosphate in absorbed from the bowel, most of which is rapidly excreted into the urine.
INTRODUCTION: The COVID-19 pandemic has affected millions worldwide, causing mortality and multi-organ morbidity. Neurological complications have been recognized. This study aimed to assess brain structural, microstructural, and connectivity alterations in patients with COVID-19-related olfactory or cognitive impairment using post-acute (time from onset: 264[208-313] days) multi-directional diffusion-weighted MRI (DW-MRI).
METHODS: The study included 16 COVID-19 patients with cognitive impairment (COVID-CM), 35 COVID-19 patients with olfactory disorder (COVID-OD), and 14 controls. A state-of-the-art processing pipeline was developed for DW-MRI pre-processing, mean diffusivity and fractional anisotropy computation, fiber density and cross-section analysis, and tractography of white-matter bundles. Brain parcellation required for probing network connectivity, region-specific microstructure and volume, and cortical thickness was based on T1-weighted scans and anatomical atlases.
RESULTS: Compared to controls, COVID-CM patients showed overall gray matter atrophy (age and sex corrected p = 0.004), and both COVID-19 patient groups showed regional atrophy and cortical thinning. Both groups presented an increase in gray matter mean diffusivity (corrected p = 0.001), decrease in white matter fiber density and cross-section (corrected p < 0.05), , and COVID-CM patients also displayed an overall increased diffusivity (p = 0.022) and decreased anisotropy (corrected p = 0.038) in white matter. Graph-based analysis revealed reduced network modularity, with an extensive pattern of connectivity increase, in conjunction with a localized reduction in a few connections, mainly located in the left hemisphere. The left cingulate, anterior cingulate, and insula were primarily involved.
CONCLUSION: Expanding upon previous findings, this study further investigated significant alterations in brain morphology, microstructure, and connectivity in COVID-19 patients with olfactory or cognitive disfunction. These findings suggest underlying neurodegeneration, neuroinflammation, and concomitant compensatory mechanisms. Future longitudinal studies are required to monitor the alterations over time and assess their transient or permanent nature.
Participants will receive lopinavir/ritonavir twice daily for up to 104 weeks. Upon confirmation of virologic failure, emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) once a day will be added to their regimen.
Participants receive 2\*20 milligram (mg) tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 of period 1. After a washout period of 5 to 9 days participants will receive matching placebo from Day 1 to Day 5 of period 2.
Participants in the IV stratum received intravenous (IV) paricalcitol and, if hypercalcemia (calcium \>= 10.5 mg/dL), received 30 mg of oral cinacalcet. Paricalcitol was dosed at 0.07 mcg/kg with titration every 2 weeks.
The invention relates to an allosterically-controlled hairpin ribozyme. The invention further relates to a polynucleotide comprising a hairpin ribozyme, whereby the hairpin ribozyme comprises at least one substrate-binding domain A and a domain B. The catalytic activity is dependent on contact of domain A with domain B and a domain C is arranged between domain A and domain B. Said domain C connects domain A and domain B and comprises a nucleic acid binding to a target molecule. Furthermore, the invention relates to a polynucleotide, comprising a hairpin ribozyme containing at least one substrate-binding domain A and a catalytic domain B. The catalytic activity is dependent on contact of domain A with domain B and a domain C is arranged between domain A and domain B. Said domain C connects domain A and domain B and comprises a nucleic acid at least partially complementary to a nucleic acid binding to a target molecule.
The invention discloses an anti-cicatricial topical drug film containing anti-mast cell medicine and the preparation method. The anti-cicatricial topical drug film contains silica gel drug film, which is added with anti-mast cell medicine. The anti-cicatricial topical drug film of the invention is capable of effectively curing scar. After the drug combination in the drug film is screened and the drug combination is optimized, the anti-cicatricial topical drug film does not change the hormone levels of patients. Thereby, the invention is not only fit for curing scars of common population and children, but also capable of curing wounds except severe infection. Besides, the product improves the treating effect of gel scar drug film and widens the scope of treating population. The anti-cicatricial topical drug film of the invention is characterized by simple preparation process and low cost.
BACKGROUND: Although the challenges of living with chronic pain are widely documented within existing literature, to our knowledge, the acceptability of pain for people living with persistent pain, has not been fully explored. The current study aims to explore what 'acceptable pain' means to adults living with chronic non-cancer pain (CPCP).
METHODS: A total of 117 participants (aged 21 to 77 years) worldwide were recruited using opportunity sampling. Participants completed an online qualitative survey. Qualitative analysis of the data used inductive reflexive thematic analysis.
RESULTS: Two themes were generated. The first theme-'I grin and bear it', described participants' desire and drive to push through their pain to live their daily lives to the best of their ability. Contrastingly, the second theme-'Thriving versus surviving', placed greater importance on leading meaningful and happy lives despite living with chronic pain. The acceptability of pain was found to be influenced by various factors including, but not limited to, pain severity, mental health, functionality, productivity and quality of life.
CONCLUSIONS: It can be difficult to identify when a clinically significant change in pain has occurred from numerical pain rating scales. We have identified two themes and a number of factors influencing the acceptability of pain. Understanding individuals' unique perceptions of what constitutes 'acceptable pain' is crucial for clinicians when assessing and managing chronic pain. Pain is a highly subjective experience, and what one person considers acceptable may differ significantly from another person's perspective. Recommendations to improve healthcare services for adults living with CNCP are proposed and directions for future research are explored.
SIGNIFICANCE: Adults with CNCP have unique experiences of living with and managing their chronic pain. CNCP was found to affect biological, psychological, and social aspects of an individual's life. The acceptability of pain exists on a continuum where adjacent parts are not noticeably different from each other, but the extremes of the continuum appear very distinct. The acceptability of pain is determined by the different factors that influence an individuals' ability to function on a day-to-day basis as well as their quality of life. While acceptable pain and manageable pain represent distinct aspects of the pain experience, the relationship between them is complex and plays a crucial role in how individuals cope with and adapt to chronic pain.
On Days 9 to 15, rifampin 600 mg will be administered QD in the morning. On Day 16, a single dose of sitravatinib malate 100 mg will be coadministered with rifampin followed by a 72 hour PK sample collection period. Rifampin QD dosing will continue on Days 17 to 22 to maintain steady state during the PK sample collection period.
Compositions comprising porcine retinal cells and methods for using the compositions to treat retinal disorders are described. The porcine retinal cells are preferably fetal neural retina cells or retinal pigment epithelial cells. The porcine retinal cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine retinal cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine retinal cells are obtained from a pig predetermined to be free from organisms which originate in pig and which are capable of transmitting infection or disease to the recipient subject. The porcine retinal cells of the present invention can be used to treat a xenogeneic subject having a retinal disorder (e.g., a human with retinis pigmentosa, light damaged retina and macular degeneration) by introducing the cells into the retina of the subject.
The utility model relates to a live bifidobacterium, lactobacillus, enterococcus and bacillus cereus tetrad dispersible agent, in particular to a bifidus tetrad pharmaceutical granulation dispersible agent used for treating intestinal canal diseases belonging to the field of medicinal and pharmaceutical substances. The utility model is a live tetrad dispersible agent with bifidobacterium, lactobacillus, enterococcus and bacillus cereus. The dispersible agent is composed of a visceral pharmaceutical mixture and a carrier dispersible agent bag which is composed of an inner packaging bag and an outer packaging bag. The inner packaging bag is composed of at least an auxiliary bag. The outer packaging bag enwraps the inner packaging bag. A dispersible agent bag continuously sealed by a plurality of auxiliary bags of the utility model aiming at the bifidus tetrad pharmaceutical granulations used for treating intestinal canal diseases is invented according to different dosages. The form of the inner bag is a concatenation sphere or a concatenation pillow shape. The inner packaging bags are integrally enwrapped by the outer packaging bag. The carry over is convenient and the raw material is saved. The patient can tear the dispersible agent bag in which the dosage is matched with the state of illness and age according to different states of illness and ages simultaneously. To take medicine is convenient for the patient.
A computer-implemented method for facilitating maintenance of a medical analyzer device is disclosed. The method comprises obtaining a plurality of measurement results associated with a plurality of quality control (QC) measurements performed by a plurality of medical analyzer devices on a plurality of predefined QC samples. Each QC sample is associated with a predefined target range and each medical analyzer device is associated with a peer group of medical analyzer devices. The method further comprises, for each medical analyzer device, evaluating the obtained measurement results against measurement results of the associated peer group in order to identify a deviation of at least one QC measurement parameter. Then, if a deviation above a predefined threshold is identified, the method further comprises obtaining an action log of the medical analyzer device. The action log comprises data indicative of any previously transmitted maintenance actions associated with the medical analyzer device. Moreover, the method comprises obtaining at least one suggested maintenance action for the medical analyzer device associated with the identified deviation based on a type of QC measurement parameter that is associated with the identified deviation. The method further comprises, selecting a maintenance action for the medical analyzer device associated with the identified deviation from the at least one suggested maintenance action based on the obtained action log. Furthermore, the method comprises transmitting, to a device for managing the medical analyzer device associated with the identified deviation, data indicative of an instruction to execute the selected maintenance action for the medical analyzer device.